Kelly Markowitz
Impact in
-
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
-
- Glioma Diagnosis and Treatment
Papers in
- Oncology 7
- Cancer Immunotherapy and Biomarkers 4
- Pancreatic and Hepatic Oncology Research 3
- CAR-T cell therapy research 2
- PARP inhibition in cancer therapy 1
-
- Immune cells in cancer 3
- Immunotherapy and Immune Responses 2
- Co-authors
- Gregory Lawrence Beatty (6 shared papers)Meredith L. Stone (5 shared papers)Max Miller Wattenberg (4 shared papers)Devora Delman (4 shared papers)Stacy K. Thomas (2 shared papers)Nandita Bose (2 shared papers)Jae Woo Lee (2 shared papers)Michael Jon Chisamore (1 shared paper)
- Journals
- JCI Insight (1 paper)Nature Communications (1 paper)Nature Immunology (1 paper)Cell Reports Medicine (1 paper)Nature Cancer (1 paper)
- Partner nations
- United StatesSwitzerlandFrance
In The Last Decade
Kelly Markowitz
7 papers receiving 291 citations
Kelly Markowitz's Hit Papers
Peers
Comparison fields: 5 of 29
- Oncology 164
- Genetics 55
- Immunology 63
- Biotechnology 6
- Hepatology 6
Countries citing papers authored by Kelly Markowitz
This map shows the geographic impact of Kelly Markowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly Markowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly Markowitz more than expected).
Fields of papers citing papers by Kelly Markowitz
This network shows the impact of papers produced by Kelly Markowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly Markowitz. The network helps show where Kelly Markowitz may publish in the future.
Co-authors
The 25 scholars most cited alongside Kelly Markowitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial Hit paper breakdown → | 2024 | 133 |
| 2 | 2023 | 41 | |
| 3 | 2025 | 34 | |
| 4 | 2023 | 31 | |
| 5 | 2024 | 28 | |
| 6 | 2024 | 26 | |
| 7 | 2026 | 1 | |
| 8 | 2026 | 0 |
About Kelly Markowitz
Kelly Markowitz is a scholar working on Oncology, Immunology, Genetics, Molecular Biology and Nuclear Energy and Engineering, having authored 8 papers that have together received 294 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), Immune cells in cancer (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), CAR-T cell therapy research (2 papers), Immunotherapy and Immune Responses (2 papers), Glioma Diagnosis and Treatment (1 paper), PARP inhibition in cancer therapy (1 paper) and Gut microbiota and health (1 paper). The work is most often cited by research in Oncology (164 citations), Genetics (55 citations), Immunology (63 citations), Biotechnology (6 citations) and Hepatology (6 citations). Kelly Markowitz has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Gregory Lawrence Beatty, Meredith L. Stone, Max Miller Wattenberg, Devora Delman, Stacy K. Thomas, Nandita Bose, Jae Woo Lee, Michael Jon Chisamore, Mingen Liu and Mark T. Uhlik. Their work appears in journals such as JCI Insight, Nature Communications, Nature Immunology, Cell Reports Medicine and Nature Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.